Tenderwize
Back to tender search

Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 713 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

75/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

75 / 100

Complexity

30 / 100

Risk factors

No estimated contract value or volume is provided. Potential revenue is unknown.

The contract automatically ends upon patent expiry or loss of market exclusivity, potentially shortening the contract t...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclude discount agreements (Rabattverträge) for the active substance Tralokinumab with all eligible pharmaceutical entrepreneurs.
  • Pharmaceutical supply to insured persons of TK and participating health insurers.
Show full summary

This is an Open House procedure by Techniker Krankenkasse (TK) and affiliated health insurers to conclude discount agreements (Rabattverträge) for the active substance Tralokinumab, in accordance with § 130c SGB V. The procedure is open to all qualified pharmaceutical entrepreneurs who hold a valid marketing authorization for Tralokinumab. Contracts are offered on standardized, non-negotiable terms with no exclusivity. The contract duration is up to 24 months, starting 01 August 2026 and ending at the latest 31 July 2028. The procedure is not a public procurement under EU law; it remains continuously open for new participants throughout its validity. No estimated contract value, award criteria, or competitive selection are specified – eligible participants are automatically accepted upon confirming their eligibility. Documents are available but were not analyzed. Place of performance is throughout Germany.

Risks

No estimated contract value or volume is provided. Potential revenue is unknown.

The contract automatically ends upon patent expiry or loss of market exclusivity, potentially shortening the contract t...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must have seat in Germany, another EU Member State, or EEA state (§ 9 Abs. 2 AMG).
  • Must hold a valid marketing authorization for Tralokinumab or be legally entitled to market the product.

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

Discount agreement for Tralokinumab. Standardized terms, no exclusivity, available to all qualified pharmaceutical entrepreneurs holding a valid marketing authorization for the active substance.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jul 2026 - Jul 2028

Category

Pharmaceutical products

Deadline

Deadline Jul 30, 2028

Procurement Details

Publication date
17 Jun 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
418152-2026

Documents (1)

Similar tenders